-
-
n this issue: Stop smoking drug Chantix rates stronger warning from FDA; Type 2 diabetes surgery on the way?; Vytorin study inconclusive; Influenza A virus found resistant to Tamiflu; FDA actions.
-
A prospective observational study was conducted to assess diagnostic and therapeutic efficacies of a daily routine CXR and to evaluate the impact of discontinuing this practice. The setting was a 10-bed mixed medical-surgical ICU of a non-academic teaching hospital in The Netherlands.
-
Most of the attention on catheter-related bloodstream infections (CR-BSI) in the ICU focuses on central venous catheters (CVC), a bias that likely derives, in part, from the 2002 Centers for Disease Control guidelines which stipulate that arterial catheters (AC) have "low infection ratesrarely associated with bloodstream infections.
-
For years, scientists have been talking about how digital breast tomosynthesis (DBT), a technique that enables radiologists to view three-dimensional images of the breast, is going to revolutionize breast screening. The development and approval process has taken much longer than anyone anticipated, but that hasn't dampened the enthusiasm of leading researchers, many of whom now believe that approval from the Food and Drug Administration (FDA) for at least one DBT system will come within the next year.
-
Numerous trials have shown that ultrasound offers certain advantages over other imaging technologies in determining whether some lesions are cancerous. However, data presented thus far are less convincing when ultrasound is used as a screening methodology.
-
A prophylactic procedure performed before surgery this fall on N.J. Gov. Jon Corzine could raise the public's awareness of using radiation to treat heterotopic ossification (HO), says Carol Kornmehl, MD, director of radiation oncology at St. Mary's Passaic (NJ) Hospital and author of the book, The Best News About Radiation Therapy.
-
Toward the end of 2007, about 500 documented cases of nephrogenic systemic fibrosis (NSF), a painful condition that affects skin and internal organs, were reported worldwide. However, that number is very likely an underestimation.
-
-
While results from the Digital Mammographic Imaging Screening Trial (DMIST) trial, published in 2005, demonstrated that digital mammography outperformed conventional film-screen mammography for a large percentage of women,1 data from the Food and Drug Administration (FDA) show that the technology has only been adopted by 25% of the 8,000 imaging sites in the United States.2
